Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Market Cap	146.51M
Revenue (ttm)	48.21M
Net Income (ttm)	14.86M
Shares Out	19.96M
EPS (ttm)	0.72
PE Ratio	10.16
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,167
Average Volume	31,601
Open	7.68
Previous Close	7.60
Day's Range	7.34 - 7.68
52-Week Range	5.20 - 11.20
Beta	0.81
RSI	43.87
Earnings Date	Sep 16, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: NWRN

Financial Performance

Financial numbers in EUR